A Phase 2 interventional study of gemcitabine and docetaxel in Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 5 under way, none of them phase 3. Gemcitabine · Carcinoma, Non-Small-Cell Lung.
Among the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, this one is the 67th largest by enrollment of the 152 interventional ones that give a count, is one of 18 that started in 2003, is one of 109 in phase 2, and was the 49th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →4 of the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
169 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 121 · Phase 3 28 · Phase 4 3
First in 1997; this study’s year is marked. 18 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is close to the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 53 across the 152 interventional studies. Of the 133 that completed or were terminated, 40 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 169 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 93rd largest by enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2003, is one of 73 in phase 2, and was the 20th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 169 studies testing gemcitabine in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: gemcitabine · Drug: cisplatin · Drug: etoposide · Radiation: radiation therapy
Drug: gemcitabine · Drug: docetaxel · Drug: cisplatin · Drug: etoposide · Radiation: radiation therapy
After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
Also known as: LY188011, Gemzar
Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
Also known as: Taxotere
As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
Also known as: Platinol, Platinol-AQ, CDDP
As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
Also known as: Toposar®, VePesid®, Etopophos®, VP-16, Etoposide phosphate
In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
2-Year Survival
Percentage of participants alive at 2 years.
Time frame: 2 years
Number of Patients With Overall Tumor Response
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) =30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) =20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. The total number of CRs plus PRs equals overall response rate (ORR).
Time frame: randomization and every 3 months up to 2 years of post-study followup
Progression-Free Survival
Defined as the time from randomization into consolidation treatment to the first date of documented disease progression or death. Progression-free survival time was censored at the date of the last follow-up visit at which disease was assessed for patients who were still alive and who had not progressed.
Time frame: baseline to measured progressive disease up to 2057 days
Overall Survival
Overall survival is the duration from enrollment to death from any cause. For patients who are alive, overall survival is censored at the last contact.
Time frame: baseline to date of death from any cause up to 2057 days
Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization
LCSS measures physical \& functional dimensions. The patient scale contains 9 items, 3 summation \& 6 symptom items. Each item is marked on a visual analog scale (0=low; 100=high). The mean of the 6 symptoms is used to calculate the average symptom burden index (ASBI). Improved=mean ASBI assessments from any 2 consecutive improved post-randomization assessments was at least 0.5 standard deviation (SD) below pre-randomization ASBI; worse=mean ASBI from any 2 consecutive post-randomization assessments was at least 0.5 SD above pre-randomization ASBI; stable=criteria for improved/worse not met.
Time frame: baseline to 3 months after last dose of study treatment (three 21-day cycles)
| Milestone | Gemcitabine | Gemcitabine Plus Docetaxel |
|---|---|---|
| Started | 32 | 32 |
| Completed | 27 | 20 |
| Not completed | 5 | 12 |
| Withdrew: Adverse event | 2 | 6 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Disease progression | 0 | 1 |
| Withdrew: Other | 1 | 2 |
Percentage of participants alive at 2 years.
| percentage of participants | Gemcitabine | Gemcitabine Plus Docetaxel |
|---|---|---|
| 2-Year Survival | 40.6 | 55.7 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR) =30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) =20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. The total number of CRs plus PRs equals overall response rate (ORR).
| participants | Gemcitabine | Gemcitabine Plus Docetaxel |
|---|---|---|
| Number of Patients With Overall Tumor Response | 24 | 27 |
Defined as the time from randomization into consolidation treatment to the first date of documented disease progression or death. Progression-free survival time was censored at the date of the last follow-up visit at which disease was assessed for patients who were still alive and who had not progressed.
| days | Gemcitabine | Gemcitabine Plus Docetaxel |
|---|---|---|
| Progression-Free Survival | 162.5 (82.0 to 239.0) | 408.0 (141.0 to 708.0) |
Overall survival is the duration from enrollment to death from any cause. For patients who are alive, overall survival is censored at the last contact.
| days | Gemcitabine | Gemcitabine Plus Docetaxel |
|---|---|---|
| Overall Survival | 492.5 (299.0 to 1034.0) | 899.0 (498.0 to 1583.0) |
LCSS measures physical \& functional dimensions. The patient scale contains 9 items, 3 summation \& 6 symptom items. Each item is marked on a visual analog scale (0=low; 100=high). The mean of the 6 symptoms is used to calculate the average symptom burden index (ASBI). Improved=mean ASBI assessments from any 2 consecutive improved post-randomization assessments was at least 0.5 standard deviation (SD) below pre-randomization ASBI; worse=mean ASBI from any 2 consecutive post-randomization assessments was at least 0.5 SD above pre-randomization ASBI; stable=criteria for improved/worse not met.
| participants | Gemcitabine | Gemcitabine Plus Docetaxel |
|---|---|---|
| Improvement | 8 | 5 |
| Stable | 10 | 9 |
| Worse | 2 | 8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine | — | 13/32 (40.6%) | 32/32 (100%) |
| Gemcitabine Plus Docetaxel | — | 18/32 (56.3%) | 32/32 (100%) |
| Event | Gemcitabine | Gemcitabine Plus Docetaxel |
|---|---|---|
| Pneumonia NOSInfections and infestations | 4/32 | 5/32 |
| Anaemia NOSBlood and lymphatic system disorders | 0/32 | 4/32 |
| DehydrationMetabolism and nutrition disorders | 0/32 | 4/32 |
| Pneumonitis NOSRespiratory, thoracic and mediastinal disorders | 1/32 | 3/32 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/32 | 2/32 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/32 | 2/32 |
| NauseaGastrointestinal disorders | 1/32 | 2/32 |
| Oesophagitis NOSGastrointestinal disorders | 1/32 | 2/32 |
| Death NOSGeneral disorders | 2/32 | 0/32 |
| PyrexiaGeneral disorders | 1/32 | 2/32 |
| Event | Gemcitabine | Gemcitabine Plus Docetaxel |
|---|---|---|
| NauseaGastrointestinal disorders | 23/32 | 28/32 |
| FatigueGeneral disorders | 19/32 | 26/32 |
| Anaemia NOSBlood and lymphatic system disorders | 18/32 | 24/32 |
| NeutropeniaBlood and lymphatic system disorders | 19/32 | 23/32 |
| Vomiting NOSGastrointestinal disorders | 17/32 | 22/32 |
| AlopeciaSkin and subcutaneous tissue disorders | 14/32 | 20/32 |
| AnorexiaMetabolism and nutrition disorders | 16/32 | 17/32 |
| CoughRespiratory, thoracic and mediastinal disorders | 17/32 | 16/32 |
| Diarrhoea NOSGastrointestinal disorders | 9/32 | 16/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 14/32 | 16/32 |
| Age Continuous(years) | Gemcitabine | Gemcitabine Plus Docetaxel | Total |
|---|---|---|---|
| Median | 59.5 ± 7.31 | 59.5 ± 9.61 | 59.5 ± 8.48 |
| Sex: Female, Male(Participants) | Gemcitabine | Gemcitabine Plus Docetaxel | Total |
|---|---|---|---|
| Female | 5 | 6 | 11 |
| Male | 27 | 26 | 53 |
| Race/Ethnicity, Customized(participants) | Gemcitabine | Gemcitabine Plus Docetaxel | Total |
|---|---|---|---|
| Caucasian | 18 | 19 | 37 |
| Black | 1 | 2 | 3 |
| Asian | 13 | 10 | 23 |
| Hispanic | 0 | 1 | 1 |
| Region of Enrollment(participants) | Gemcitabine | Gemcitabine Plus Docetaxel | Total |
|---|---|---|---|
| United States | 18 | 20 | 38 |
| Argentina | 1 | 2 | 3 |
| China | 10 | 7 | 17 |
| Korea, Republic of | 3 | 3 | 6 |
| Eastern Oncology Cooperative Group (ECOG) Performance Status(units on a scale) | Gemcitabine | Gemcitabine Plus Docetaxel | Total |
|---|---|---|---|
| 0 - Fully Active | 12 | 14 | 26 |
| 1 - Ambulatory, Restricted Strenuous Activity | 19 | 18 | 37 |
| 2 - Ambulatory, No Work Activities | 1 | 0 | 1 |
The record gives a start of Mar 2003, a primary completion of Nov 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Cisplatin · Etoposide
Carcinoma, Non-Small-Cell Lung →